Nuveen Asset Management LLC Raises Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)

Nuveen Asset Management LLC lifted its position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) by 6.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 192,424 shares of the company’s stock after acquiring an additional 11,571 shares during the quarter. Nuveen Asset Management LLC owned 0.27% of C4 Therapeutics worth $693,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in CCCC. Sei Investments Co. acquired a new stake in shares of C4 Therapeutics in the fourth quarter valued at approximately $45,000. Kazazian Asset Management LLC acquired a new stake in shares of C4 Therapeutics in the fourth quarter valued at $51,000. Lazard Asset Management LLC purchased a new stake in C4 Therapeutics during the fourth quarter worth about $81,000. Y Intercept Hong Kong Ltd purchased a new position in C4 Therapeutics in the 4th quarter valued at approximately $83,000. Finally, Intech Investment Management LLC boosted its holdings in C4 Therapeutics by 11.1% in the fourth quarter. Intech Investment Management LLC now owns 30,150 shares of the company’s stock valued at $109,000 after purchasing an additional 3,024 shares during the period. 78.81% of the stock is owned by institutional investors and hedge funds.

C4 Therapeutics Stock Down 4.5%

Shares of CCCC stock opened at $1.47 on Friday. C4 Therapeutics, Inc. has a 52-week low of $1.09 and a 52-week high of $7.66. The stock’s 50-day moving average price is $1.41 and its 200 day moving average price is $2.70. The stock has a market capitalization of $104.38 million, a PE ratio of -0.86 and a beta of 2.93.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.11. The firm had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $3.54 million. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. Analysts expect that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, UBS Group raised C4 Therapeutics to a “hold” rating in a research report on Friday, February 14th.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.